Novartis hit with $178 million verdict in cancer drug patent dispute [Reuters]
Novartis AG (NVS)
Last novartis ag earnings: 4/28 01:00 am
Check Earnings Report
US:NYSE Investor Relations:
novartis.com/investors
Company Research
Source: Reuters
The company and law firm names shown above are generated automatically based on the text of the article. We are improving this feature as we continue to test and develop in beta. We welcome feedback, which you can provide using the feedback tab on the right of the page. (Reuters) - A California federal jury found Thursday that Novartis Pharmaceuticals infringed two patents owned by Daiichi Sankyo's Plexxikon Inc with its cancer drug Tafinlar and awarded Plexxikon $178 million in damages, according to Plexxikon's lawyer. Plexxikon sued Novartis in 2017 , alleging the company infringed two patents covering Plexxikon's melanoma drug Zelboraf, which inhibits the growth of cancer cells that have a mutated form of a certain gene. "We are delighted with the verdict and the vindication that Plexxikon made groundbreaking innovations that have made a difference in the lives of cancer patients," Plexxikon's attorney Daralyn Durie of Durie Tangri said in an email. Durie also said that th
Show less
Read more
Impact Snapshot
Event Time:
NVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVS alerts
High impacting Novartis AG news events
Weekly update
A roundup of the hottest topics
NVS
News
- Novartis (NVS) to Report Q1 Earnings: What to Expect? [Yahoo! Finance]Yahoo! Finance
- The Bicycle Day Dream Bike: A Carbon Fiber Hommage To Albert Hofmann [Forbes]Forbes
- Amarna Therapeutics announces appointment of Aurelia Caparrós as new Chief Business Officer [Yahoo! Finance]Yahoo! Finance
- US FDA mandates label updates on CAR-T cancer therapies [Reuters]Reuters
- Exploring Analyst Estimates for Novartis (NVS) Q1 Earnings, Beyond Revenue and EPS [Yahoo! Finance]Yahoo! Finance
NVS
Earnings
- 1/31/24 - Miss
NVS
Sec Filings
- 2/15/24 - Form S-8
- 2/2/24 - Form SC
- 1/31/24 - Form 6-K
- NVS's page on the SEC website